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Abstract Pituitary adenylate cyclase activating polypeptide
(PACAP) is a multifunctional neuropeptide expression of
which has been found in various tumors of the brain and
peripheral organs. Despite numerous studies, the exact role
the peptide plays in the development and progression of
tumors is not fully understood. In the present study, we inves-
tigated the effect of PACAP on human retinoblastoma Y79
cell viability. We found that both PACAP38 and PACAP6-38,
a selective PAC1 receptor antagonist, did not affect Y79 cell
viability at nanomolar concentrations, but when used at 1–
5 μM potently reduced cell survival in a dose-dependent
manner. PACAP27 and maxadilan, a high affinity agonist of
PAC1 receptors, had negligible effects. Two membrane-
penetrating analogs of PACAP38 inactive at PAC1/VPAC
receptors, [Disc6]PACAP38 and FITC-Ahx-PACAP11-38, al-
so decreased viability of Y79 cells, albeit with lower potency
than PACAP38. The cytotoxic effect of PACAP38 was aug-
mented by p38, MEK1/2, and JNK inhibitors, indicating that
high concentrations of the peptide might decrease the activity
of these kinases, leading to cell death. It is suggested that the
cytotoxic activity of PACAP38 and PACAP6-38 against hu-
man retinoblastoma Y79 cell line may result from their inter-
action with target sites other than PAC1 and VPAC receptors,
but this is yet unknown.
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Abbreviations
JNK c-Jun N-terminal kinases
LDH Lactate dehydrogenase
MAPK Mitogen-activated protein kinase
PKA Protein kinase A
PKC Protein kinase C
PACAP Pituitary adenylate cyclase activating polypeptide
PAC1 Selective receptor for PACAP
VIP Vasoactive intestinal peptide
VPAC1 Type 1 receptor for PACAP and VIP
VPAC2 Type 2 receptor for PACAP and VIP
Introduction
Pituitary adenylate cyclase activating polypeptide (PACAP) is
a multifunctional neuropeptide which belongs to the secretin/
glucagon/vasoactive intestinal peptide (VIP)/growth hormone
releasing factor peptides superfamily (Vaudry et al. 2009). It
was isolated for the first time from an extract of ovine hypo-
thalamus and named after its ability to stimulate adenylate
cyclase in cultured rat anterior pituitary cells (Miyata et al.
1989). Endogenously, PACAP exists in two forms, the dom-
inating PACAP38 and C-truncated PACAP27 which shares
68 % of structural similarity with VIP (Vaudry et al. 2009).
Consistent with its widespread distribution in the central ner-
vous system and peripheral tissues, PACAP has been found to
exert pleiotropic physiological functions acting as a hormone,
a neurohormone, a neurotransmitter, and a trophic factor. The
peptide has been shown to be involved in modulation of
neurotransmitter release, neuroprotection, vasodilation,
bronchodilation, activation of intestinal motility, increase of
insulin and histamine secretion, as well as stimulation of cell
multiplication and/or differentiation (Vaudry et al. 2009).
PACAP38 and PACAP27 exert their biological activity by
stimulating specific membrane bound G protein-coupled re-
ceptors, namely PAC1, VPAC1 and VPAC2. PAC1 receptor
exhibits much higher affinity to both forms of PACAP than to
J. Wojcieszak : J. B. Zawilska (*)
Department of Pharmacodynamics, Medical University of Lodz,
Muszynskiego 1 Street, Lodz 90-151, Poland
e-mail: jolanta.zawilska@umed.lodz.pl
J Mol Neurosci (2014) 54:463–468
DOI 10.1007/s12031-014-0248-0
VIP, whereas VPAC1 and VPAC2 receptors have similar af-
finity for VIP and PACAPs. Several splice variants of PAC1
receptor have been identified and characterized. They express
marked differences not only in terms of tissue localization but
also in second messengers coupling (Vaudry et al. 2009).
PACAP can also bind to other target sites, such as CART
(Lin et al. 2011) and secretin receptors (Felley et al. 1992).
Recently, it has been demonstrated that PACAP and its syn-
thetic derivatives can cross plasma membrane via a receptor-
independent manner: by a direct translocation, endocytosis
through clathrin-coated pits and macropinocytosis or by a
clathrin-independent caveolar endocytosis (Doan et al.
2012a, 2012b). Furthermore, PACAP has been found to evoke
re-dimerization of PAC1 receptor on the nucleus and, when
used at high concentrations, to cause translocation of PAC1
dimers into nucleus accompanied with increased cAMP levels
in the nuclear fraction (Yu et al. 2013).
Expression of PACAP has been found in various tumors of
the brain (gliomas, neuroblastomas) and peripheral organs,
such as pheochromocytomas, pituitary, pancreas, and ovarian
carcinomas (Vaudry et al. 2009). Despite numerous studies,
the exact role the peptide plays in the development and pro-
gression of tumors is not fully understood. It has been dem-
onstrated that depending on the cell line, PACAP can increase
or decrease cancer cell viability. Thus, PACAP38 stimulated
proliferation of rat C6 glioma cells (Sokołowska and Nowak
2008) and prevented apoptosis of androgen-independent pros-
tate cancer PC-3 cells (Gutiérrez-Cañas et al. 2003). On the
other hand, PACAP27 reduced proliferation of two human
colonic tumor cell lines: DLD-1 and Caco-2 (Lelièvre et al.
1998), and PACAP38 inhibited proliferation of primary
medulloblastoma-derived tumor spheres (Cohen et al. 2010).
Furthermore, an increased colorectal tumor incidence was
observed in PACAP knockout mice (Nemetz et al. 2008).
Although the presence of specific functional PAC1 receptors
has been demonstrated in human retinoblastoma Y79 cell line
(Olianas et al. 1996; Dautzenberg et al. 1999), a potential role
PACAP might play in this type of tumor remains to be
elucidated. Therefore, the aim of the current work was to
investigate whether PACAP affected viability of Y79 cells




PACAP27, PACAP38, and PACAP6-38 were purchased from
PolyPeptide Laboratories (Strasbourg, France). Maxadilan was
purchased from Bachem AG (Bubendorf, Switzerland).
[Disc6]PACAP38, FITC-Ahx-PACAP11-38, FITC-Ahx-
PACAP28-38, and FITC-Ahx-TAT(48-60) were generous gifts
from Dr. Myriam Letourneau and Dr. Alain Fournier from
Laboratoire d’Études Moléculaires et Pharmacologiques des
Peptides, INRS–Institut Armand-Frappier, Université du
Québec, Canada. MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-




imidazole), GF 109203X (3-(N-[dimethylamino]propyl-
3-indolyl)-4-(3-indolyl)maleimide), and H89 (N-[2-
(p-bromocinnamylamino)ethyl]-5-isoquinoline sulfonamide)
were purchased from Sigma-Aldrich (Poznań, Poland). RPMI
1640 medium, heat inactivated fetal bovine serum, penicillin,
and streptomycin were purchased from Life Technologies
(Warsaw, Poland).
Cell Culture
Y79 cells, purchased from the European Collection of Cell
Cultures (ECACC, Porton Down, UK), were cultured in
RPMI 1640 medium supplemented with 10 % fetal bovine
serum and penicillin-streptomycin (10,000 U/ml) at 37 °C in a
humidified atmosphere with 5 % CO2. Upon reaching the
density of approx. 900,000 cells/ml, cells were passaged into
a new flask or resuspended in a fresh, serum-free medium and
seeded into 96-well plates at a density of 20,000 cells/well in
80 μl of medium. Following overnight incubation, solutions
of PACAP27, PACAP38, PACAP6-38, maxadilan,
[Disc6]PACAP38, FITC-Ahx-PACAP11-38, FITC-Ahx-
PACAP28-38 or FITC-Ahx-TAT(48-60) were added into the
wells. After incubation for 24 h, measurements of cell viability
were conducted using MTT and LDHe assays.
MTTAssay
Cell viability and mitochondrial function were measured
by assessment of 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) reduction to
formazan by mitochondrial dehydrogenases. Following
exposure to the tested compounds, solution of MTT
(0.5 mg/ml) was added and cells were incubated for
3 h at 37 °C. Formazan crystals were solubilized in
isopropanol acidified with 0.04 N HCl and absorbance,
proportional to the number of viable cells, was mea-
sured at 570 nm using Bio-Rad microplate reader model
680.
LDHe Assay
Cellular membrane integrity was assessed by extracellular
lactate dehydrogenase activity measurement using LDH
Cytotoxicity Assay (ScienCell Research Laboratories,
Carlsbad, CA, USA), following manufacturer’s instructions.
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Data Analysis
Data were expressed as the mean±standard error of the mean
(SEM) values and were analyzed for statistical significance
using one-way ANOVA, followed by post hoc Student-
Newman-Keul’s test using InStat version 3.06 for Windows
(GraphPad, San Diego, CA, USA).
Results
PACAP38 and PACAP6-38 are Cytotoxic to Y79 Cells
Y79 cells were challenged with various peptides and cell
viability, and mitochondrial function was measured by MTT
test. Twenty-four-hour incubation of the cells with nanomolar
(0.1–100 nM) concentrations of PACAP38 had no effect on
their viability (data not shown). When the peptide was used in
higher concentrations (1–5 μM) it produced a dose-dependent
decrease in cell viability, with a calculated IC50=1.7 μM
(Fig. 1a). The cytotoxic effect of PACAP38 was not abolished
by a PAC1 receptor antagonist, PACAP6-38. In fact,
PACAP6-38 (1–5 μM) also produced a concentration-
dependent reduction of Y79 cell viability with a similar po-
tency and IC50=2.1 μM (Fig. 1b). The suppressive effects of
both peptides on Y79 cell viability were additive (Fig. 2). On
the contrary, incubation of Y79 cells with PACAP27 (0.1–
5 μM) and maxadilan (1 and 2 μM), a high affinity selective
agonist of PAC1 receptors, did not significantly affect their
viability (data not shown). Two membrane-penetrating ana-
logs of PACAP38 inactive at PAC1/VPAC receptors,
[Disc6]PACAP38 and FITC-Ahx-PACAP11-38, decreased vi-
ability of Y79 cells, albeit with lower potency than PACAP38
(Fig. 3). Another cell penetrating peptide, FITC-Ahx-TAT48-
60, which has no structure similarity to PACAP, and mem-
brane non-penetrating C-terminal fragment of PACAP, FITC-
Ahx-PACAP28-38, used at a 10 μM concentration were in-
active (data not shown).
In another set of experiments, we examined effects of
PACAP38 and PACAP6-38 on Y79 cell viability by measur-
ing extracellular activity of lactate dehydrogenase (LDH).
LDH is a cytosolic enzyme present in most eukaryotic cells,
which is released into the culture medium upon cell death due
to the damage of plasma membrane. Incubation of Y79 cells
with PACAP38 and PACAP6-38, both at 2 μM, for 24 h
resulted in a significant increase of extracellular LDH activity
by 68 and 95 %, respectively (Fig. 4).
Effects of Signal Transduction Inhibitors
on PACAP38-Induced Decrease in Y79 Cell Viability
In order to shed some light on biochemical mechanism(s)
underlying the cytotoxic effect of PACAP38 on Y79 cells,
cells were preincubated for 1 h with the following signal
transduction inhibitors: U0126 (MEK1/2 inhibitor; 10 μM),
SB203580 (p38 inhibitor; 10 μM), SP600125 (JNK inhibitor;
10 μM), GF 109203X (PKC inhibitor; 2.5 μM), and H89
(PKA inhibitor; 5 μM). U0126, SB203580, and SP600125
significantly facilitated the PACAP38-induced decrease in
Y79 cell survival (Fig. 5), whereas the other tested inhibitors
were inactive (data not shown).
Discussion
Using different experimental approaches (RT-PCR analysis,
radioligand binding of 125I-PACAP27, and measurement of
adenylyl cyclase activity), the presence of functional PAC1
receptors has been demonstrated in Y79 human retinoblasto-
ma cells (Olianas et al. 1996; Dautzenberget al. 1999). Despite
these findings, a potential role PACAP might play in this type
Fig. 1 Concentration-dependent effect of PACAP38 (panel a) and
PACAP6-38 (panel b) on viability of Y79 cells. Cells were incubated
with the peptides (0.1–5 μM) for 24 h and cell viability was analyzed by
MTT test. Data are presented as mean±SEM of 6–12 values per group
and expressed as a percentage of the respective control
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of tumor is at present unknown. In the current study, we
analyzed effects of PACAP38 on viability of Y79 human
retinoblastoma cell line. Using two complementary methods,
namely, MTT test and extracellular LDH assay, we found that
the peptide strongly, albeit with a low potency, reduced sur-
vival of Y79 cells. Surprisingly, PACAP6-38 not only did not
block the effect of PACAP38, but produced reduction of Y79
cell viability with a similar potency to PACAP38, while
PACAP27 and maxadilan, a selective high affinity peptidergic
agonist of PAC1 receptors, had neglible activity. The cytotoxic
effect of PACAP38 and PACAP6-38 was characteristic to
Y79 cells as they were inactive at two other studied cell types,
i.e., neuroblastoma SH-SY5Y and rat cortical astrocytes
(Wojcieszak J, unpublished data).
It should be noted that although PACAP6-38 acts as the
antagonist of PAC1 and VPAC2 receptors (Vaudry et al. 2009),
there are also reports demonstrating that in certain models this
peptide can behave similarly to PACAP38. Thus, in isolated
rat tracheae, both peptides inhibited the release of substance P,
calcitonin gene-related peptide, and somatostatin evoked by
both chemical excitation and electrical field stimulation of
capsaicin-sensitive afferents (Reglodi et al. 2008). In human
cytotrophoblast cells, PACAP38 and PACAP6-38 stimulated
ERK1/2 and JNK phosphorylation, while they both inhibited
p38 MAPK phosphorylation (Reglodi et al. 2008). In another
study, both PACAP38 and PACAP6-38 caused enhancement
of phagocytosis in mouse macrophages with a similar poten-
cy, while PACAP6-27 produced less pronounced increase,
and the effect PACAP27 was even weaker (Ichinose et al.
1995). In chicken limb bud-derived chondrogenic cells,
PACAP38 and PACAP6-38 stimulated cell proliferation and
enhanced expression of PAC1 receptor, Sox9 protein, and
calcineurin (Juhasz et al. 2013).
In our studies, PACAP38 and PACAP6-38 were effective
when used at high, micromolar concentrations. Similar data
have been recently reported by other authors. Baun et al.
(2012) have shown degranulation of rat peritoneal mast cells
after incubation with micromolar concentrations of
PACAP38. By analogy to our results, PACAP38 and
PACAP6-38 produced similar effects, whereas PACAP27
triggered markedly weaker response and maxadilan was inac-
tive (Baun et al. 2012). Furthermore, PACAP38 applied at
micromolar concentration increased expression of proinflam-
matory cytokines, IL-1β and TNF-α, in grass carp head
kidney and head kidney leucocytes (Wang et al. 2013).
Several lines of evidence suggest that the cytotoxic effect
of PACAP on human retinoblastoma Y79 cells is independent
Fig. 3 Effect of [Disc6]PACAP38 and FITC-Ahx-PACAP11-38 on via-
bility of Y79 cells. Cells were incubated with the peptides for 24 h and
cell viability was analyzed by MTT test. Data are presented as mean±
SEM of 6–12 values per group and expressed as a percentage of the
respective control.***p<0.001 vs. control
Fig. 4 Effect of PACAP38 and PACAP6-38 on viability of Y79 cells.
Cells were incubated with 2 μM of the peptides for 24 h and cell viability
was analyzed by assessment of cell membrane integrity using LDHe test.
Data are presented as mean±SEM of 6–12 values per group and
expressed as a percentage of the respective control. ***p<0.001 vs.
control
Fig. 2 The additive effect of PACAP38 and PACAP6-38 on viability of
Y79 cells. Cells were incubated with 1 μM of the peptides for 24 h and
cell viability was analyzed by MTT test. Data are presented as mean±
SEM of 6–12 values per group and expressed as a percentage of the
respective control. ***p<0.001 vs. control
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of PAC1 and VPAC receptors and might be related to the
peptide sequence. Firstly, the calculated IC50 values for
PACAP38 and PACAP6-38 were around 2 μM,while binding
affinity of PACAP38 to PAC1/VPAC receptors is within
nanomolar range:Kd≈0.5 nM at the full length PAC1 receptor,
Kd≈1.0 nM at VPAC1 and VPAC2 receptors, and the affinity
of PACAP6-38 for PAC1 is approximately 10-fold lower than
that of PACAP38 (Bourgault et al. 2009; Vaudry et al. 2009).
Secondly, maxadilan, the potent and selective PAC1 receptor
agonist, and PACAP27, the C-truncated form of PACAP38,
were inactive. Thirdly, [Disc6]PACAP38 and FITC-Ahx-
PACAP11-38, the membrane permeable synthetic analogs of
PACAP38, produced similar, but less pronounced reduction in
human retinoblastoma Y79 cell viability. FITC-Ahx-
PACAP11-38 is an inactive analog of PACAP38 obtained by
the removal of 10 N-terminal amino acids. In the original
peptide, these amino acids form a Asx-turn-like motif and
N-capping secondary structure responsible for the receptor
recognition, selectivity, and activation (Bourgault et al.
2009; Doan et al. 2011, 2012b). [Disc6]PACAP38 is another
receptor-inactive analog of PACAP38. It is produced by the
substitution of Phe6 residue essential for the biological activity
of PACAP with a conformationally constrained 1,3-dihydro-
2H-isoindole carboxylic acid (Bourgault et al. 2009). Both
analogs conserve helical properties of PACAP38 that underlie
the membrane-penetrating activity of the peptide (Doan et al.
2011, 2012b). The fact that PACAP38 and its fragments evoke
similar effects in Y79 cells in relatively high concentrations
might suggest that their common, shorter metabolite, arising in
low quantity, may be responsible for the cytotoxicity, or that the
peptide fragment responsible for cytotoxicity is rapidly metab-
olized. PACAP38 can be metabolized in vivo and in vitro by
dipeptidyl peptidase IV (DPP IV), intracellular enzymes and
human plasma enzymes, giving rise to shorter fragments, such
as PACAP3-38, PACAP5-38, PACAP22-38, PACAP1-21,
PACAP1-20, PACAP1-19, PACAP1-37, PACAP1-34,
PACAP1-30, and PACAP1-29 (Bourgault et al. 2008; Doan
et al. 2012a; Zhu et al. 2003).Metabolites that may be produced
from PACAP38 by Y79 cells are at present unknown.
The cytotoxic activity of PACAP38 against human retino-
blastoma Y79 cell line might result from its interaction with
target sites other than PAC1 and VPAC receptors, but this is
yet unknown. PACAP38 has been found to have higher ability
to cross cell membrane than PACAP27 in three cell lines,
CHO-K1, HEK293, and HeLa, with a significant increase of
intracellular fraction at micromolar concentration. It has been
suggested that the efficacy of peptides to penetrate into the cell
may depend on the cell membrane composition or the cell size
(Doan et al. 2012a). There is evidence that PACAP can bind to
receptors localized inside the cell, i.e., on the nucleus (Doan
et al. 2012a; Yu et al. 2013). The fact that high concentrations
of both PACAP38 and PACAP6-38 exert similar cytotoxic
effects in Y79 cells could be explained by their limited Y79
cell membrane permeability, whereas PACAP27, due to its
lower permeability, may not reach sufficient concentration
inside the cells. On the other hand, FITC-Ahx-PACAP28-
38, inactive in our studies, contains a highly basic C-terminal
fragment of PACAP38 and does not enter the intracellular
compartment, a property that is likely due to the disordered
secondary structure of this segment (Doan et al. 2012a).
Neither of signal transduction inhibitors used
abolished the effect of PACAP38, an observation indi-
cating that the peptide-induced cell death does not in-
volve activation of PKA, PKC, MEK1/2, p38, and JNK
kinases. On the other hand, MEK1/2, p38, and JNK
inhibitors augmented PACAP38 cytotoxicity, which
may suggest that high concentrations of the peptide
inhibit those kinases, leading to the cell death.
Fig. 5 Effect of signal
transduction inhibitors on the
PACAP38-induced decrease in
viability of Y79 cells. Following
1 h pretreatment with U0126
(MEK1/2 inhibitor; 10 μM);
SB203580 (SB, p38 inhibitor;
10 μM); SP600125 (SP, JNK in-
hibitor; 10 μM) cells were incu-
bated for 24 h with PACAP38
(2 μM). Cell viability was ana-
lyzed by MTT test. Data are pre-
sented as mean±SEM of 6–12
values per group and expressed as
a percentage of the respective
control (C). a indicates p<0.001
vs. control, b indicates p<0.001
vs. PACAP38
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In summary, we found that PACAP38 and PACAP6-38 as
well as two PACAP38 analogs, [Disc6]PACAP38 and FITC-
Ahx-PACAP11-38, inactive at PAC1/VPAC receptors, pro-
duced marked decrease in Y79 cells viability at micromolar
concentrations. It is suggested that the cytotoxic activities of
the peptides is independent from activation of PAC1/VPAC
receptors. Further studies are needed in order to define the
exact molecular mechanism(s) of PACAP38-induced cytotox-
icity in Y79 human retinoblastoma cells.
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